Brief: Ipsen: EC Conditional Marketing Authorization For Ojemda (Tovorafenib)
April 22 (Reuters) - Ipsen SA IPN.PA: EUROPEAN COMMISSION GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR OJEMDA (TOVORAFENIB) Source text: ID:nGNE8Mgg8K Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio